Related Experiment Video

Updated: Jun 21, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Current state of systemic therapy of metastatic renal cell carcinoma]

A S Merseburger1, S Waalkes, M A Kuczyk

  • 1Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover (MHH), Carl-Neuberg-Strasse 1, 30625, Hannover, Germany. merseburger.axel@mh-hannover.de

Der Urologe. Ausg. A
|August 12, 2009
PubMed

Insights

Systemic therapy for metastatic renal cell carcinoma has evolved significantly. Five new targeted drugs, including multikinase inhibitors and mTOR inhibitors, now offer molecular-based treatment options.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Metastatic renal cell carcinoma (mRCC) treatment landscape has transformed.
  • Cytokine-based chemotherapy was the primary therapy until recently.
  • The last five years have seen major advancements in systemic therapy for mRCC.

Purpose:

  • To provide an overview of newly approved targeted therapies for mRCC.
  • To critically discuss current treatment strategies and future directions in mRCC management.

Summary:

  • Five novel targeted drugs have been approved for mRCC treatment.
  • These include multikinase inhibitors (sunitinib, sorafenib), mTOR inhibitors (everolimus, temsirolimus), and VEGF inhibitor (bevacizumab) in combination with interferon-alpha.
  • These agents offer molecular-based therapeutic mechanisms, improving upon older chemotherapy regimens.

Impact:

  • Represents a paradigm shift in mRCC systemic therapy.
  • Offers improved efficacy and targeted mechanisms compared to traditional chemotherapy.
  • Highlights the rapid progress in molecularly targeted treatments for advanced cancers.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.